Endpoint Validation Study (0524A-015)

NCT00533676 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Flushing

Interventions

DRUG: MK0524A, /Duration of Treatment : 8 Weeks
DRUG: Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks

Sponsor

Merck Sharp & Dohme LLC